Clinical trials
HER2 Positive clinical trials
Below are recruiting her2 positive clinical trials, each written for real people, not researchers. We’re tracking 345 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07112053RecruitingPhase 2
Vaccine with hormone therapy or chemo for advanced breast cancer
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
Seattle, WashingtonAges 18 years+ - NCT06278870RecruitingPhase 3
New drug combo vs standard for HER2+ advanced breast cancer
This trial compares two drug combinations for HER2-positive breast cancer that has spread. It tests a newer drug (Disitamab Vedotin + Pyrotinib) against a standard treatment (THP) as a first treatment option.
Guangzhou, GuangdongAges 18–75 - NCT07192432RecruitingPhase 1/Phase 2
Gene therapy for HER2-positive cancer
This trial tests a new gene therapy for people with HER2-positive cancer. It is for two groups: those with advanced cancer that has worsened after treatment, and those with early-stage cancer at high risk of coming back. The goal is to see if the therapy can safely help shrink tumors or prevent return.
Los Angeles, CaliforniaAges 18 years+ - NCT05306041RecruitingPhase 2
Pre-surgery hormone therapy with or without PI3K inhibitor
This trial tests whether giving hormone-blocking treatment before surgery works better when combined with an added targeted drug for certain breast cancers. It may help shrink the tumor and improve outcomes for people whose tumors have specific hormone and genetic features.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT04985266RecruitingPhase 2
Watch blood DNA for early breast cancer return, then add palbociclib
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
AngersAges 18 years+ - NCT07299825RecruitingPhase 2
Study of A166 for advanced HER2-positive breast cancer
This trial tests a new drug called A166 for people with HER2-positive breast cancer that has spread or can't be removed. It is for those who have already tried up to five treatments, including a specific type of HER2 antibody-drug conjugate.
Zhenzhou, HenanAges 18–75 - NCT05575804RecruitingPhase 1/Phase 2
GQ1001 plus pyrotinib for HER2-positive metastatic breast cancer
This trial tests a combination of two targeted drugs, GQ1001 and pyrotinib, for people with HER2-positive breast cancer that has spread to other parts of the body and has not responded to at least one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07023861Enrolling by invitationEarly Phase 1
New imaging test for HER2-positive cancers
This trial tests a new imaging method that uses a radioactive tracer to find HER2-positive cancer cells in the body. It may help doctors see tumors more clearly in people with stomach, breast, or bladder cancer.
Wuxi, JiangsuAges 15–75 - NCT07593976RecruitingPhase 2
New PET scan to predict breast cancer treatment response
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
RouenAges 18 years+ - NCT06756932RecruitingPhase 1
Bcl-2 inhibitor combo for advanced HR+ breast cancer
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
Iowa City, IowaAges 18 years+ - NCT04332588RecruitingPhase 1
Testing PET/MRI monitoring for HER2-positive breast cancer before surgery
This early-phase study looks at how well PET/MRI scans can monitor treatment response in people with HER2-positive breast cancer before surgery. You may be asked to undergo specific scans during “neoadjuvant” therapy (treatment given before the main operation).
Birmingham, AlabamaAges 18 years+ - NCT07527741Recruiting
HER2-Positive Breast Cancer Treatment Patterns Study
This study tracks how patients with HER2-positive early-stage breast cancer receive treatment and stick to their treatment plan after their care moves to local hospitals. The trial helps doctors understand whether patients follow through with their recommended therapy when treated closer to home.
Loznica, Bolnička 65Ages 18 years+ - NCT07739511RecruitingPhase 1/Phase 2
Oral paclitaxel for HER2-positive breast cancer before surgery
This trial tests an oral form of paclitaxel combined with standard HER2 therapy given before surgery for HER2-positive breast cancer. It aims to find the best dose and see how well it works.
Guiyang, GuizhouAges 18–70 - NCT04030507Recruiting
Brain MRI screening during chemotherapy for breast cancer
This trial checks the brain using MRI in people with breast cancer that has spread outside the breast or can’t be fully removed. The goal is to screen for brain involvement and see how MRI findings fit with treatment timing, when it’s safe to do so.
Boston, MassachusettsAges 18 years+ - NCT06744465Recruiting
Light-based monitoring for breast cancer during chemo
This study uses a special light-based device to monitor breast cancer during chemotherapy before surgery. It is for women with HER2-positive or triple-negative breast cancer who are planning chemotherapy first.
Indianapolis, IndianaAges 18 years+ - NCT05388149RecruitingPhase 2
Neratinib plus Kadcyla to treat leftover HER2 breast cancer
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
Toronto, OntarioAges 18 years+ - NCT05406635Recruiting
Imaging vs blood tests to guide heart-safe HER2 treatment
This trial compares whether special heart imaging or blood tests better helps monitor heart safety while you receive HER2-targeted therapy (like trastuzumab, with or without pertuzumab) plus chemotherapy. It may help doctors catch early heart stress and choose the safest treatment plan for you.
AalborgAges 18–90 - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT05325632RecruitingPhase 2
HER2 breast cancer vaccine plus chemo and targeted antibodies
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
Tampa, FloridaAges 18 years+ - NCT06369285RecruitingPhase 2
Alisertib and hormone therapy for advanced breast cancer
This trial tests a new drug, alisertib, combined with hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread or come back and is no longer curable. It may be an option if you've already tried at least two hormone therapies and a CDK4/6 inhibitor.
Birmingham, AlabamaAges 18 years+ - NCT06272799Recruiting
T-DM1 after incomplete response to initial breast cancer therapy
This trial is for people with HER2-positive breast cancer who still had cancer after initial chemotherapy. It tests the safety and effectiveness of a drug called T-DM1 (Kadcyla) given after surgery to reduce the chance of the cancer coming back.
Rome, RomeAges Any age - NCT07065435RecruitingPhase 2
RC48 with Avastin or Pyrotinib for HER2+ breast cancer after T-DXd
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Nanjing, JiangsuAges 18–75 - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Anchorage, AlaskaAges 18 years+ - NCT05760612RecruitingPhase 3
After breast cancer surgery, test neratinib plus trastuzumab
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
GuangzhouAges 18–70
Hear when a new HER2 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 positive?
- Yes. Clin2 currently lists 345 recruiting her2 positive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.